Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BJTJ-0052
- Development stage
- Preclinical
- Lead developer
- Beijing Tuobixi Pharmaceutical
- Modality
- Small Molecules
01
Overview
BJTJ-0052 is a preclinical-stage drug candidate being developed by Beijing Tuobixi Pharmaceutical (also known as Beijing Tuojie Pharmaceutical) for the treatment of blood disorders. Based on pipeline documentation, the indication is likely hemochromatosis (referred to in Chinese as '血色病'), a condition characterized by excessive iron accumulation in the body. BJTJ-0052 is part of the BJTJ series of drug candidates, many of which are developed through partnerships or licensing agreements with Meiji Seika Pharma. As a preclinical asset, specific details regarding its molecular target and pharmacological profile remain proprietary and have not been extensively disclosed in public clinical literature.
Beyond the preview
Go deeper on BJTJ-0052.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BJTJ-0052.